adalimumab-afzb (Abrilada) vs adalimumab-atto (Amjevita)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-afzb (Abrilada)
Marketed by Pfizer
NCT02480153 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled Phase 3 trial in 597 patients comparing PF-06410293 with adalimumab-EU on a hard clinical endpoint: ACR20 response at Week 12. The primary equivalence analysis succeeded, with the 95% confidence interval for the response rate difference falling entirely within the prespecified -14% to +14% margin (observed difference -2.98%, 95% CI -10.38% to 4.44%). The large sample size, blinding, active comparator, and met primary endpoint together provide strong evidence of equivalent efficacy.
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33% (met)
Result source: NCT02480153
adalimumab-atto (Amjevita)
Marketed by Amgen
NCT01970475 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial of 526 participants, with adalimumab as the comparator. The clinical primary endpoint, ACR20 response at week 24, met the prespecified equivalence criterion: the 90% confidence interval for the response risk ratio (0.954–1.133) was within the equivalence margins (0.738–1.355).
Reported efficacy
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): ABP 501 74.6 percentage of participants | Adalimumab 72.4 percentage of participants (met)
Result source: NCT01970475
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-afzb (Abrilada) | adalimumab-atto (Amjevita) |
|---|---|---|
| ACR20 | 68.3% vs 71.3%vs Adalimumab-EUNCT0248015311 other results
| 74.6% vs 72.4%vs AdalimumabNCT019704752 other results
|
| ACR50 | 62.9% vs 55.6%vs Adalimumab-EUNCT0248015311 other results
| 49.2% vs 52%vs AdalimumabNCT01970475 |
| ACR70 | 36.4% vs 31.9%vs Adalimumab-EUNCT0248015311 other results
| 26% vs 22.9%vs AdalimumabNCT01970475 |
| DAS28-CRP remission | —Not reported | —Not reported |
| HAQ-DI, change | -0.7 vs -0.7vs Adalimumab-EUNCT0248015311 other results
| —Not reported |
| Modified Sharp score, change | —Not reported | —Not reported |
ACR20
- adalimumab-afzb (Abrilada)
- 68.3% vs 71.3%vs Adalimumab-EUNCT02480153
11 other results
- 69.4% vs 68% NCT02480153
- 61.3% vs 59.7% NCT02480153
- 51.9% vs 52.3% NCT02480153
- 31.3% vs 32% NCT02480153
- 78.1% vs 73.7% NCT02480153
- 83.5% vs 78% NCT02480153
- 86.6% vs 84.4% NCT02480153
- 86.6% vs 82.2% NCT02480153
- 83.4% vs 77.8% NCT02480153
- 82.3% vs 78.5% NCT02480153
- 82.7% vs 79.3% NCT02480153
- adalimumab-atto (Amjevita)
- 74.6% vs 72.4%vs AdalimumabNCT01970475
2 other results
- 63.5% vs 62.5% NCT01970475
- 35.4% vs 24.5% NCT01970475
ACR50
- adalimumab-afzb (Abrilada)
- 62.9% vs 55.6%vs Adalimumab-EUNCT02480153
11 other results
- 64.3% vs 49.6% NCT02480153
- 61.1% vs 51.9% NCT02480153
- 59.7% vs 49.6% NCT02480153
- 59.6% vs 54.7% NCT02480153
- 61.8% vs 56.3% NCT02480153
- 45.1% vs 47% NCT02480153
- 39.7% vs 39.7% NCT02480153
- 34% vs 33.3% NCT02480153
- 27.6% vs 27.3% NCT02480153
- 17.8% vs 14.3% NCT02480153
- 8.4% vs 6% NCT02480153
- adalimumab-atto (Amjevita)
- 49.2% vs 52%vs AdalimumabNCT01970475
ACR70
- adalimumab-afzb (Abrilada)
- 36.4% vs 31.9%vs Adalimumab-EUNCT02480153
11 other results
- 38.5% vs 32.6% NCT02480153
- 36% vs 26.7% NCT02480153
- 33.9% vs 30.4% NCT02480153
- 29.6% vs 31% NCT02480153
- 31.1% vs 30.4% NCT02480153
- 21.5% vs 22% NCT02480153
- 16.5% vs 19% NCT02480153
- 12.5% vs 11.7% NCT02480153
- 8.1% vs 8.7% NCT02480153
- 3.7% vs 3.7% NCT02480153
- 0.7% vs 2% NCT02480153
- adalimumab-atto (Amjevita)
- 26% vs 22.9%vs AdalimumabNCT01970475
DAS28-CRP remission
- adalimumab-afzb (Abrilada)
- —Not reported
- adalimumab-atto (Amjevita)
- —Not reported
HAQ-DI, change
- adalimumab-afzb (Abrilada)
- -0.7 vs -0.7vs Adalimumab-EUNCT02480153
11 other results
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.6 vs -0.6 NCT02480153
- -0.5 vs -0.5 NCT02480153
- -0.5 vs -0.5 NCT02480153
- -0.4 vs -0.5 NCT02480153
- -0.3 vs -0.4 NCT02480153
- -0.3 vs -0.3 NCT02480153
- adalimumab-atto (Amjevita)
- —Not reported
Modified Sharp score, change
- adalimumab-afzb (Abrilada)
- —Not reported
- adalimumab-atto (Amjevita)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. adalimumab-afzb (Abrilada): 3 of 5 rows · adalimumab-atto (Amjevita): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-afzb (Abrilada) | adalimumab-atto (Amjevita) |
|---|---|---|
| DAS28-CRP absolute change · score | -2.5 vs -2.6 Adalimumab-EU score @ 18wka,b NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | -2.3 vs -2.17 Adalimumab score @ 18wka,b NCT01970475 · Phase 3 |
| Dropout rate | —Period 1: PF-06410293c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results—Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 — NCT04230213 · Phase 3 | 8%d NCT01970475 · Phase 3 |
| Discontinued due to AEs | —Period 1: PF-06410293c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results—Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 — NCT04230213 · Phase 3 | 2.7%d NCT01970475 · Phase 3 |
| Serious AEs | 4%Period 1: PF-06410293c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results1.4%Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 3.5%Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 1.4% NCT04230213 · Phase 3 | 3.8%d NCT01970475 · Phase 3 |
| Most frequent reported AEs | c viral upper respiratory tract infection 7.1% rheumatoid arthritis 1.7% nasopharyngitis 0% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more resultsviral upper respiratory tract infection 5.3% rheumatoid arthritis 1.4% nasopharyngitis 0.4% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 nasopharyngitis 5% rheumatoid arthritis 4.7% viral upper respiratory tract infection 0.4% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cPopulation comparability has not been reviewed for 1 of these studies.
- dPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-afzb (Abrilada)
show 4 more results
show 4 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
+ 42 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-afzb (Abrilada)'s landscape · adalimumab-atto (Amjevita)'s landscape